Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

deleobuvir

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
ABSTRACT Introduction: Cytochrome P450 (CYP) 2C8 is a drug metabolizing enzyme of major importance. The lipid-lowering drug… Expand
2016
2016
The drug-drug interaction (DDI) potential of deleobuvir, an hepatitis C virus (HCV) polymerase inhibitor, and its two major… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
2015
2015
Deleobuvir is a potent inhibitor of the hepatitis C virus nonstructural protein 5B polymerase. In humans, deleobuvir underwent… Expand
  • table 1
  • table 2
  • table 3
2015
2015
The safety and efficacy of the interferon‐free combination of faldaprevir (NS3/A4 protease inhibitor), deleobuvir (BI 207127, non… Expand
Highly Cited
2014
Highly Cited
2014
BACKGROUND & AIMS Chronic hepatitis C virus (HCV) infection is characterised by a failure of virus-specific CD8+ T cells that is… Expand
  • figure 1
  • figure 2
  • figure 3
2014
2014
Conformational restrictions of flexible torsion angles were used to guide the identification of new chemotypes of HCV NS5B… Expand
2014
2014
ABSTRACT Patients with advanced hepatic fibrosis or cirrhosis with chronic hepatitis C virus (HCV) infection represent an unmet… Expand
Highly Cited
2013
Highly Cited
2013
BACKGROUND Interferon-free regimens would be a major advance in the treatment of patients with chronic hepatitis C virus (HCV… Expand
  • table 1
  • table 2
  • table 3
  • table 4
2013
2013
Background Faldaprevir (BI 201335) and deleobuvir (BI 207127) are direct-acting antiviral agents under development for the… Expand
  • figure 1
  • table 1
2013
2013
ABSTRACT Deleobuvir (BI 207127) is an investigational oral nonnucleoside inhibitor of hepatitis C virus (HCV) NS5B RNA polymerase… Expand